[{"id":"e892208a-36f9-4d6f-a38c-e7cd64d31bd9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03659136","created_at":"2021-01-18T17:57:27.537Z","updated_at":"2025-02-25T12:26:58.565Z","phase":"Phase 2","brief_title":"The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread","source_id_and_acronym":"NCT03659136","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • exemestane • xentuzumab (BI-836845)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 11/28/2018","start_date":" 11/28/2018","primary_txt":" Primary completion: 08/30/2021","primary_completion_date":" 08/30/2021","study_txt":" Completion: 05/11/2022","study_completion_date":" 05/11/2022","last_update_posted":"2025-02-24"},{"id":"99da48d9-3c70-49ca-9c4f-caad6ae87340","acronym":"","url":"https://clinicaltrials.gov/study/NCT03099174","created_at":"2021-01-18T15:16:18.304Z","updated_at":"2024-07-02T16:35:16.312Z","phase":"Phase 1","brief_title":"This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.","source_id_and_acronym":"NCT03099174","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2 • ER • ALK • PGR","pipe":" | ","alterations":" EGFR mutation • HER-2 negative • ALK translocation","tags":["HER-2 • ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 negative • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • xentuzumab (BI-836845)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 05/04/2017","start_date":" 05/04/2017","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 05/30/2024","study_completion_date":" 05/30/2024","last_update_posted":"2024-03-05"},{"id":"66396fe9-178e-4c39-9051-ad73dc1e48d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02123823","created_at":"2021-01-18T09:50:27.098Z","updated_at":"2024-07-02T16:36:17.652Z","phase":"Phase 1","brief_title":"BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT02123823","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • exemestane • xentuzumab (BI-836845)"],"overall_status":"Completed","enrollment":" Enrollment 164","initiation":"Initiation: 05/15/2014","start_date":" 05/15/2014","primary_txt":" Primary completion: 11/25/2016","primary_completion_date":" 11/25/2016","study_txt":" Completion: 12/14/2021","study_completion_date":" 12/14/2021","last_update_posted":"2022-02-03"}]